Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded to “Strong-Buy” at Freedom Capital

Alnylam Pharmaceuticals (NASDAQ:ALNY) was upgraded by investment analysts at Freedom Capital from a “hold” rating to a “strong-buy” rating in a research note issued on Tuesday,Zacks.com reports.

A number of other research analysts have also recently issued reports on ALNY. Raymond James Financial reiterated an “outperform” rating and issued a $472.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, January 12th. Needham & Company LLC dropped their price target on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a report on Thursday, February 12th. Bank of America reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 12th. Wall Street Zen cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. Finally, Oppenheimer initiated coverage on Alnylam Pharmaceuticals in a research note on Wednesday, January 7th. They issued an “outperform” rating and a $500.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $477.96.

Alnylam Pharmaceuticals Stock Up 0.0%

Shares of NASDAQ ALNY opened at $332.68 on Tuesday. Alnylam Pharmaceuticals has a 52-week low of $205.87 and a 52-week high of $495.55. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76. The business has a fifty day moving average of $369.58 and a two-hundred day moving average of $423.61. The stock has a market cap of $44.12 billion, a PE ratio of 194.55 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.61). The firm had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The company’s revenue for the quarter was up 84.9% compared to the same quarter last year. During the same quarter last year, the business earned ($0.65) EPS. As a group, equities research analysts expect that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 9,577 shares of the stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $362.86, for a total value of $3,475,110.22. Following the transaction, the chief executive officer directly owned 78,411 shares in the company, valued at $28,452,215.46. This represents a 10.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Jeffrey V. Poulton sold 2,780 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $362.87, for a total transaction of $1,008,778.60. Following the completion of the transaction, the executive vice president directly owned 57,465 shares in the company, valued at approximately $20,852,324.55. The trade was a 4.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 36,578 shares of company stock worth $12,416,105. Insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Thematics Asset Management bought a new stake in Alnylam Pharmaceuticals during the second quarter worth $1,995,000. Mediolanum International Funds Ltd bought a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at about $11,389,000. Teacher Retirement System of Texas increased its stake in shares of Alnylam Pharmaceuticals by 3.2% during the 2nd quarter. Teacher Retirement System of Texas now owns 36,408 shares of the biopharmaceutical company’s stock worth $11,872,000 after purchasing an additional 1,123 shares during the last quarter. Rakuten Investment Management Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth about $14,205,000. Finally, Generali Asset Management SPA SGR raised its holdings in shares of Alnylam Pharmaceuticals by 6,368.0% in the 3rd quarter. Generali Asset Management SPA SGR now owns 3,234 shares of the biopharmaceutical company’s stock valued at $1,475,000 after purchasing an additional 3,184 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Trending Headlines about Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Canaccord Genuity raised its price target on ALNY to $429 and maintained a “buy” rating, signaling meaningful upside from current levels and helping lift investor sentiment. Read More.
• Positive Sentiment: HC Wainwright reaffirmed a “buy” and set a $510 price target, a notably higher bull case that reinforces optimistic analyst views on Alnylam’s growth prospects. Read More.
• Positive Sentiment: Freedom Capital Markets issued an upgrade on ALNY, which added to the positive analyst chorus and likely contributed to upticks in trading interest. Read More.
• Neutral Sentiment: Several analyst notes trimmed near‑term targets or updated models but generally kept confidence in 2026 growth — a mixed signal that tempers both the bullish and bearish narratives. Read More.
• Neutral Sentiment: Independent valuation pieces describe a mixed picture: bullish fair‑value models versus share-price returns, suggesting some analysts still see long-term upside but valuation expectations vary. Read More.
• Neutral Sentiment: Reported short‑interest figures in the feeds show zero/NaN values and a 0.0 days‑to‑cover — likely a data/reporting artifact rather than actionable new short pressure; treat this as non‑conclusive until exchange data confirms.
• Negative Sentiment: Significant insider selling announced this week: CEO Yvonne Greenstreet sold 6,958 shares (~$310 avg) and several EVPs (including Kevin Fitzgerald, Jeffrey Poulton, Tolga Tanguler, Pushkal Garg) sold multiple blocks at ~$310–332, each trimming mid‑single‑digit percentages of their holdings. Large, clustered insider sales can weigh on near‑term sentiment even if executed for diversification or tax reasons. Read More.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.